Background: Effort-induced myocardial ischemia (EMI) has been seldom described. Aims of our study were (A) to evaluate the prevalence of EMI during long-lasting 5-FU infusion; (B) to identify possible risk factors of EMI during 5-FU infusion.
introduction
The most threatening side-effects of the fluoropyrimidines 5-fluorouracil (5-FU) and capecitabine are myocardial ischemia (MI), ventricular arrhythmias (VA) and sudden death [1, 2] . The reported incidence ranges from 1% to 18%, is more frequent during continuous infusions (c.i.); no patient-related risk factors have been identified so far [3] [4] [5] [6] [7] [8] [9] [10] [11] . Asymptomatic electrocardiogram (ECG) changes and arrhythmias have been described, suggesting that the cardiotoxicity is probably underestimated [12] . According to most reports, MI occurs usually at rest and is characterized by ST segment elevation at ECG, which are typical of coronary vasospasm; left ventricular dysfunction may be observed. Symptoms, ECG and echocardiographic changes may disappear quickly after drug discontinuation or even last several days; the risk of relapsing ischemia at rechallenge is high [13] [14] [15] . We first described in 2001 three cases of effort-related myocardial ischemia (EMI) during 5-FU c.i., and recently a case during capecitabine therapy; additional single cases of EMI have been reported [16] [17] [18] [19] . After our first observations, we decided to assess the incidence and characteristics of EMI during 5-FU infusion in a prospective study. No similar studies have been published so far.
The primary aim of this study was to assess the incidence of EMI among a group of patients receiving 5-FU c.i. lasting >46 h and without rest ischemia. Secondary aim was to assess the clinical and ECG characteristics of this kind of cardiotoxicity, the possible predictive factors and if a subgroup or high-risk patients might be identified. For this second aim, we also included in the analysis the three patients already described in our previous publication [16] . All the patients were examined before CT by a cardiologist reporting risk factors for coronary artery disease (CAD), clinical history, physical examination and 12 leads ECG. Additional exams were planned whenever considered necessary. The 5-FU solutions were prepared immediately before infusion and protected from light exposure to avoid toxic effects due to impurities [20] . We prospectively evaluated the patients with treadmill stress test (TST) with Bruce protocol carried out during the infusion, after >46 h of c.i. Inclusion criteria were age >18, physical ability to perform a TST, patient's consent. Exclusion criteria were signs or symptoms of at rest 5-FU cardiotoxicity, c.i. infusion stopped before 46 h for any reason, any physical condition (difficulties in walking, dizziness etc.) making the TST impossible and abnormalities at rest ECG making ECG interpretation unreliable. If any signs and/or symptoms of EMI were detected, 5-FU infusion was stopped, the patient was treated with antianginal drugs and kept under monitoring as long as needed by the clinical conditions. After at least one week of 5-FU wash-out, a second TST was carried out, to exclude a previously unrecognized CAD. The protocol was approved by the local ethic committee. Cardiac ischemia was diagnosed in presence of one or more of the following: typical chest pain; >1 mm ST segment horizontal or descending depression or >1 mm ST elevation on at least two leads at stress ECG; effort-induced VA. The severity of ischemia was evaluated on the basis of ST segment depression/elevation entity, the number of ECG leads involved, the frequency and morphology of VA.
The variable considered as possible risk factors were sex, age, clinical history of cardiac disease, cardiovascular risk factors (CVRF), cardiovascular risk score according to European Society of Cardiology guidelines [21] , cardiovascular therapy, anemia, type of infusions (associated drugs, 5-FU daily dose), days of infusions and total 5-FU dose infused at the time of TST and symptoms before the TST.
Odds ratios and 95% of 5-FU effort-induced ischemia/arrhythmias and corresponding 95% confidence intervals (95% CI) according to some sex, age, tumors size and cardiac risk factors were assessed through unconditional multiple logistic regression models (SAS software 9.3, SAS Institute, Inc., NC). Results were considered to be statistically significant when P ≤ 0.05 (two sided).
results

prevalence of 5FU-induced ischemia
Of 358 patients undergoing 5-FU c.i., 130 patients were excluded: 21 (5.9%) had rest symptoms and/or ECG signs of ischemia during 5-FU infusion, in 21 5-FU infusion was stopped before the TST for other reasons, 20 had rest ECG abnormalities, 68 were unable to perform the TST or refused . Overall, 228 patients carried out at least one TST. Among the 228, 16 (7%) had a positive test, 212 a negative one. All of these 212 patients with negative stress test underwent further courses of chemotherapy without any sign or symptom of cardiotoxicity. A second TST during a new course of chemotherapy in 49 of them was all negative. Overall, in our original prospective study group of 358 patients, we observed 37 (10.3%) cases of 5-FU cardiotoxicity: 21 at rest and 16 under effort.
clinical presentation and risk factors for EMI
We considered 231 patients: 228 of this study and the 3 already described in a previous publication [16] (supplementary Figure S1 , available at Annals of Oncology online). Among the 19 patients with a positive TST, 6 had typical angina (3 mild, 3 moderate to severe) with ECG changes typical of ischemia and 13 silent ischemia. ECG changes occurred in 18 (95%) patients: in 7, a 1.5-4 mm ST segment elevation, in 9 a 1.5-7.5 mm ST depression and in two both ST segment elevation and depression (supplementary Figures S2 and S3 , available at Annals of Oncology online). Nine patients (50%) had effort-related VA, (frequent and/or repetitive in 4) causing dizziness in two (supplementary Table S1 , available at Annals of Oncology online). All the 19 patients underwent a second TST 1 week after withdrawing 5FU: in 17 it was negative; in 2, it was positive but with milder signs of ischemia. One patient with CAD had 1 mm ST depression on two leads versus 2 mm ST depression on six leads during CT. Another patient with positive stress test after 5-FU withdrawal underwent coronary angiography and successful revascularization of his CAD with postoperative negative stress test; a TST at rechallenge with 5-FU was again slightly positive. We concluded that these two patients had ischemia induced by 5FU infusion and worsened by underlying CAD.
The patients were 148 males, 83 females, age 23-80 years (mean 57.5 years). The tumors were 127 head/neck, 63 gastric or bowel, 27 breast and 14 other cancers. As regards CVRF, 38 had family history of ischemic heart disease, 21 were obese, 28 diabetics, 94 active smokers, 54 former smokers, 77 hypertensive, 55 dyslipidemic and 8 with CAD. The analysis of patients (history of CAD, single or combined CVRF) or therapy variables are summarized in Table 1 (detailed analysis of CVRF and  tumor site are in supplementary Table S2 , available at Annals of Oncology online): all were similar in the patients with and without cardiotoxicity. Only the complaint of symptoms as chest discomfort, jaw pain, dyspnea in the daily life during the first days of infusion were highly predictive of positive stress test. They were present in 8 of 19 (42%) of the patients with EMI and in only 11 of 212 (4.9%) of those without toxicity, with an odd ratio of 13.29 (95% CI 4.45-39.7) (P < 0.0001). discussion incidence Our 10.3% global incidence of ischemia (37 of 358 patients: 21 at rest and 16 under effort) is consistent with the findings of previous prospective studies on infusions lasting ≥48 h [6, 7, 10, 19] In some retrospective studies, the incidence is much lower, probably because they ignored less severe or atypical symptoms, which-in our experience-were often predictive of EMI [3, 8, 14] . We might still have underestimated the incidence missing patients with silent ischemia among the 109 who could not perform the TST [12] . As regards the ECG changes, previous observations reported mostly ST segment elevation; less frequently ST segment depression, negative T waves, nonspecific ST-T changes, QT interval prolongation, arrhythmias [4, 13, 22] . In our study, ST segment elevation or depression and VA showed the same incidence. The finding that EMI is asymptomatic in 50% of cases highlight a clinical problem: silent ischemia is as dangerous as the symptomatic form, but the patients have no warnings inducing them to stop their activity [23] . And when the infusions are administered on an ambulatory basis, there is an increased risk, because they are probably more active at home and because any ischemic attack is more dangerous when occurring out of hospital.
predicting factors
Since 5-FU may cause life-threatening events, the identification of the patients at risk would be of paramount importance [12, 24] . We did not found any individual risk factor (CAD or CVRF), according to other previous large prospective studies [10, 11, 19, 24] . The presence if CAD was considered a predisposing factor in two retrospective studies [4, 22] , which have, however, a selective bias: they record only symptomatic cases recognized by the oncologist, who may be influenced by the clinical history. Chest pain is likely to be considered angina in a patient with known CAD and misdiagnosed as nonspecific in a young woman. This selection bias might lead to both the underestimation of the incidence of 5-FU toxicity and the overestimation of the influence of cardiac diseases. However, two of our patients with CAD had milder signs of ischemia without 5-FU, as reported by Jensen [25] . According to these findings, CAD seems not to be a predisposing factor, but its presence may worsen the clinical presentation in case of superimposed cardiotoxicity. Leucovorin and Mitomycin C might raise the incidence of cardiotoxicity, but there is no agreement on this point [4, 10] . In our study, the patients receiving Leucovorin had a 1.76 risk increase, but the difference was not statistically significant (P = 0.77); however, this might be due simply to the small numbers in our series. Most of our patients were treated for head/neck cancer; a further study including more patients under FOLFOX or FOLFIRI could possibly define this point better.
Mitomycin C was never used. We did not observe any difference in incidence among the schedules considered, all with an infusion lasting >46 h. Since the patients who had cardiotoxicity during the first 2 days of infusion have been excluded, a further study with TST carried out earlier would be necessary to test the hypothesis that different regimens (with shorter infusions and lower dose) may have different risk [11, 14] . But this was not the aim of our study. The only statistically significant difference among the patients who had or had not EMI was the complaint of atypical symptoms or angina equivalents. 
practical clinical suggestions
We think that even mild or vague symptoms should be considered, suggesting a cardiologic evaluation. ECG, stress test and/or a 12-leads Holter monitoring are necessary before ruling out cardiac ischemia. Echocardiography can be useful to detect kinetics abnormalities. Patients already treated with fluoropirimidines in the past without any symptom are probably at low risk and do not need further screening. But, if they refer to some complaints during previous treatments, they should undergo a screening, as well as naïve patients. The optimal approach to early detection of mild/ asymptomatic and to prevention of severe cardiotoxicity is to plan a stress test and/or a Holter monitoring during the first course of CT in all the naïve patients undergoing 5-FU c.i. lasting >46 h. However-according to the large number of patients-it is impossible in the daily practice. We suggest a practical approach for screening ( Figure 1 ).
(i) Patients without clinical history of CAD. Have a rest ECG before starting the infusion, (for comparison should any toxicity be suspected later). In the last 2-3 days of the first infusion have a rest ECG and ask the patient for any new symptom, even if mild and/or intermittent. In case of ECG changes and/or symptoms, rule out ischemia with tests done immediately, or planned during the next 5-FU course. In case of positive stress test during 5-FU infusion, it should be repeated after at least 1 week of 5-FU wash-out, to rule out a underlying CAD.
(ii) Patients with or at high risk of CAD. Add a stress test before starting the therapy. If positive, optimize cardiovascular therapy and repeat it. If still positive, the first course should be started at reduced dosage to avoid severe ischemia in case of cardiotoxicity, and the patient should be adviced to avoid physical efforts. Plan a stress test in the last 2 days of infusion; after an uneventful course the patient may be considered at low risk.
In case of 5-FU-induced ischemia, the indication of chemotherapy should be carefully revised. Several approaches may be attempted to avoid relapsing toxicity: reducing 5-FU dosage or days of infusion; shifting to a weekly boluses regimen; adding calcium antagonists and nitrates; using alternative regimens [16, 17, 27] . Suggested alternatives may be Tegafur, Raltitrexed or Irinotecan, according to the available schedules which have been proven to be effective in the various tumors [28] . But the risk of rechallenge cannot be excluded: the choice requires a patient tailored decision by the oncologist and the cardiologist, after weighing risks and benefits. Capecitabine is not a reasonable alternative, since it is a prodrug of 5-FU, causes the same kind of toxicity and is usually given for several days rising the cumulative dosage to levels similar -or even superior-to the longest 5-FU infusions [2, 10, 15] . and 16 effort-related in the subgroup of 228 patients undergoing a TST. The global incidence corresponds to previous prospective studies, but roughly half of the cases in our experience were effort-induced: a finding never reported before. Among the patients with EMI, 68% had silent ischemia and 15% severe arrhythmias. The only factor predicting 5-FU-induced EMI was the complaint of atypical or angina equivalent symptoms at rest. The presence of cardiac disease (including CAD) should not be an exclusion criterion in planning 5-FU-based therapies, but a stress test before and a reduced dose of 5-FU during the first course is prudent. All the naïve patients should be adviced to avoid efforts during the infusion, and to refer to the general practitioner and to the oncologist of every new symptom.
A careful re-evaluation of the patient at the end of the first course of CT (rest ECG and report of any symptoms, no matter how vague) is strongly suggested. The oncologist should ask a prompt cardiologic evaluation in any case of possible cardiotoxicity. In the presence of symptoms, normal rest ECG does not exclude cardiotoxicity, and a stress test and/or a 12-leads Holter monitoring should be carried out. Patients with negative TST are unlikely to experience toxicity with further CT. The use of stress test is therefore useful both in detecting the patients at risk of major toxicities and in ruling out toxicity in presence of suspect but not definitely diagnostic symptoms or ECG changes.
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